Testing version — LOERadar is in active testing. Features and data may change.

CARBIDOPA, LEVODOPA AND ENTACAPONE (CARBIDOPA; ENTACAPONE; LEVODOPA) | LOERadar

Viewing data from:

CARBIDOPA, LEVODOPA AND ENTACAPONE

ANDA

CARBIDOPA; ENTACAPONE; LEVODOPA | A213212 | RISING PHARMA HOLDINGS INC

6 strengths0 unique patents0 unique exclusivities

Reference Listed Drug: STALEVO 100(TE code: AB)

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Feb 4, 2022	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (6)

Sort:

#001 — 12.5MG;200MG;50MG

AB

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Jan 25, 2022

No patent or exclusivity listings for this strength.

#002 — 18.75MG;200MG;75MG

AB

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Jan 25, 2022

#003 — 25MG;200MG;100MG

AB

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Jan 25, 2022

#004 — 31.25MG;200MG;125MG

AB

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Jan 25, 2022

#005 — 37.5MG;200MG;150MG

AB

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Jan 25, 2022

#006 — 50MG;200MG;200MG

AB

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Jan 25, 2022